Table 2.
Treatment success in mice infected with Burkholderia pseudomallei 1026b.
| Antibiotic | Dose (mg/kg)—administration route | Number of deaths | Median survival (days post-challenge) | B. pseudomallei load in survivals (CFU/spleen)—(total number of samples analyzed/samples with CFU > 108) |
|---|---|---|---|---|
| Untreated | Saline - sc | 10 | 4 | No survival |
| Ceftazidime | 300 - ip | 3 | Undefined (>50% survival) | 2.4 × 105−(3/1) |
| Ceftazidime | 150 - ip | 6 | 56.5 | 2.6 × 105−(4/1) |
| ARV-1502 | 5 - im | 10 | 4 | No survival |
| Ceftazidime + ARV-1502 | 150 ip + 2.5 im | 4 | Undefined (>50% survival) | 3.1 × 106−(6/1) |
| Ceftazidime + ARV-1502 | 150 ip + 5 im | 6 | 56.5 | 8.6 x 106−(4/0) |
| Ceftazidime + ARV-1502 | 150 ip + 10 im | 7 | 50 | 7.6 x 106−(3/0) |
The antibiotics were administered for 21 days, every 6 h, beginning 24 h post-challenge. After completion of the assay at day 62, surviving animals were euthanized and their spleens removed for bacterial count determination. The values in the last column are the mean of samples with < 108 CFU/spleen.